Skip to main content

Table 1 Clinical information of the patient cohort. TTP: time interval between the start of the re-irradiation treatment and the first progression

From: FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?

  Patient cohort (n = 32)
Age (years, median, range) 52 (30–77)
Sex  
 Male 17 (53.1%)
 Female 15 (46.9%)
GBM  
 Unifocal 18 (56.3%)
 Multifocal 14 (43.7%)
IDH-mutation  
 Mutated 10 (31.2%)
 Wild-type 14 (43.8%)
 Unknown 8 (25%)
MGMT-status of recurrent tumor  
 Methylated
 Not methylated
 Unknown
7 (21.9%)
8 (25%)
17 (53.1%)
Surgery of recurrent tumor before re-irradiation  
 Yes
 No
25 (78.1%)
7 (21.9%)
Time to progression (TTP) (days, median, range) 91 (18–405)
Overall survival (OS) (days, median, range) 296.5 (18–1334)
  1. OS time interval between the start of re-irradiation and death